ABSTRACT Acid extracts from rat pancreas and hypothalamus were analyzed for the presence of the antigenic determinant corresponding to the NH2 terminus of somatostatin-28 (SS28), using an antiserum directed against amino acids I to 511 ofthe 5S28 molecule. On gel permeation chromatography the majority of the immunoreactive material from each tissue extract eluted in one zone compatible with a peptide of 1250 daltons. Purification ofthis immunoreactive material by reverse-phase HPLC and cation-exchange chromatography yielded two immunoreactive peptides from each tissue extract The amino acid compositions ofboth peptides in pancreas and hypothalamus correspond to the fragment 1-12 of SS28. The more hydrophobic peptide from each tissue coeluted with synthetic SS28-(1-12) on HPLC, while the other one coeluted with synthetic [Met(O)8]SS28-(1-12). Neither native peptide coeluted with synthetic SS28-(1-12)-amide. We conclude that the prosomatostatin fragment Ser-Ala-Asn-Ser-Asn-Pro-Ala-MetAla-Pro-Arg-Glu-OH is present in both rat hypothalamus and rat pancreas.
Somatostatin was characterized in extracts of mammalian tissues as a tetradecapeptide, somatostatin-14 (SS14) (1-4, *). An NH2-terminally extended form, somatostatin-28 (SS28), was characterized in extracts of porcine intestine (5) and later in ovine (6, 7) and porcine (8) hypothalami. In these various tissues and species, the same octacosapeptide structure SerAla -Asn-Ser-Asn -Pro-Ala-Met-Ala -Pro-Arg-Glu-Arg -Lys-AlaGly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys was found. Results from recent work on murine thyroid (9) and hypothalamus (10) added further evidence for the structural invariability of the octacosapeptide sequence in different mammalian species.
The SS28 molecule contains a pair of basic residues adjacent to the SS14 sequence and now recognized as a potential cleavage site for the posttranslational processing of prohormones (11) . We hypothesized that, if SS14 originated from enzymatic cleavage of SS28, then the remaining NH2 terminus of SS28 could also be present in tissue where SS14 is found. In order to verify this hypothesis, we raised an antiserum directed against the NH2-terminal region of SS28 and analyzed tissue extracts for SS28-NH2-terminus-like immunoreactivity (SS28-Nt-LI). The present work describes the isolation and characterization of SS28- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in both rat hypothalamus and rat pancreas.
MATERIALS AND METHODS Starting Material. (i) For pilot studies, fresh pancreata or hypothalami from adult rats were used (Fig. 2). (ii) For peptide isolation, the starting material of hypothalamic origin was a side fraction obtained during the purification of rat hypothalamic SS28 (10) . Briefly, hypothalami were extracted with 2 M acetic acid containing pepstatin and phenylmethylsulfonyl fluoride (10 mg/liter each). After centrifugation, the supernatant was defatted with petroleum ether and passed through a Sepharose-4B anti-SS14 immunoaffinity column to remove all material with SS14-like immunoreactivity. Aliquots corresponding to 3000 or 12,500 hypothalami equivalent of the material that did not bind to the affinity column were selected for the present work. The starting material of pancreatic origin was a similarly prepared side fraction of an acid extract from 439 rat pancreata originally used for the characterization of pancreatic SS14 (3) .
Synthetic Peptides. SS14, SS28-Tyr, SS28-(1-12), and SS28-(1-12)-NH2 were synthesized by a solid-phase technique, described previously for SS28 (12) . [Met(0)8]SS28-(1-12) was prepared by oxidizing 10 nmol of synthetic SS28-(1-12) with a solution containing 100 nmol of chloramine-T in 30 ,ul of 50 mM sodium phosphate (pH 7.4) for 30 sec at room temperature. The resulting [Met(0)8]SS28-(1-12) was purified by HPLC.
Radioimmunoassay (RIA). Two 3-month-old male New Zealand White rabbits were injected subcutaneously at five dorsolateral sites with 2 ml of a suspension of 6 x 1010 killed Bordetella pertussis (Institut Armand-Frappier, Laval, PQ, Canada). Two days later, the emulsion for primary injection was prepared, using 8 mg ofsynthetic SS28 dissolved in 0.4 ml ofsterile NaCl solution (150 mM) in a polypropylene tube kept on ice. Methylated bovine serum albumin (2 mg in 2 ml of distilled water; Sigma) was added to the peptide solution, which was then swirled on a Vortex mixer for 10 sec. Complete Freund's adjuvant containing killed Mycobacterium butyricum (2.5 ml, Difco) and 20 mg of killed Mycobacterium tuberculosis (Cuti-BCG, Institut Armand-Frappier) were then added. The mixture was emulsified with a Polytron homogenizer (Brinkmann) while being kept in an ice bath. Each rabbit received approximately 100 intradermal injections of this emulsion. Six weeks later the animals received a booster injection, which was repeated four times every 2 weeks. For each boosting, the same preparation as for the primary injection was used except that no mycobacteria were given and one-thitd of the primary injection dose in terms of peptide and methylated bovine serum albumin was administered. The plasma obtained 12 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
10% human serum albumin solution in 50 mM sodium phosphate, pH 7.4). The tracer was purified at 40C by cation-exchange chromatography on a CM-32 CM-cellulose column (0.5 X 15 cm; Whatman) at a flow rate of 10 mVhr by eluting first with 6 ml of-0.02 M ammonium acetate (pH 4.6) and then with 0.9 M ammonium acetate (pH 4.6). The fraction corresponding to the second peak ofradioactivity (4 x 108 cpm/ml) was chosen as tracer.
The incubation buffer for RIA was 10 mM sodium phosphate (pH 7.2) containing human serum albumin at 1 mg/ml, 150 mM NaCl, 25 mM EDTA, and 0.2 M sodium acetate. The tracer (10,000 cpm in 50 1.l of buffer) was added 8 hr after the first antibody (250 ,1.). Assay tubes were incubated at 40C. After 24 hr of incubation, goat anti-rabbit plasma (60 dul) was added, together with 4% normal rabbit plasma (50 sul), for precipitation. Eight hours later the tubes were centrifuged for 30 min at 4TC at 2000 x g and the radioactivity of the precipitate was measured in a Micromedic 4/600 gamma counter.
Aliquots of column fractions (from HPLC or CM-cellulose) used for RIA were dried in a Speed-Vac concentrator (Savant) after adding 100 ,ug of human serum albumin (Pierce).
Peptide Isolation. Reverse-phase peptide extraction. The starting material corresponding to the fraction not retarded on the anti-SS14 immunoaffinity column was adjusted to pH 2.5 with acetic acid and then pumped through a column (7.5 x 25 cm) filled with octadecylsilylsilica (ODS, LRP-2, 37-to 53-,um particle size, Whatman) previously equilibrated in 0.2 M acetic acid. Peptides that bound under such conditions were then eluted with a solution of0.36 M pyridine adjusted to pH 3 with formic acid and containing 60% (vol/vol) 1-propanol, as described (14, 15) .
HPLC. A microprocessor-controlled model 332 Altex liquid chromatograph, equipped with an automatic stream-sampling fluorescamine detection system (16), was used in conjunction with C8-or C18-Ultrasphere reverse-phase semipreparative or analytical columns (5-,um particle size, Altex, Berkeley, CA). The mobile phases used with this system consisted of 0.36 M pyridine formate (pH 3) in a 1-propanol gradient, 0.5% or 0.1% trifluoroacetic acid in an acetonitrile gradient, or 0.5% heptafluorobutyric acid in an acetonitrile gradient. These mobile phases were adaptations of those introduced by Rubinstein at a flow rate of 6 ml/hr.
Amino Acid Analysis. Peptides (25-50 pmol) were hydrolyzed in sealed evacuated tubes containing 6 M HC1 and 2% thioglycollic acid for 24 hr at 110°C (19) . To quantitate cysteine, separate peptide aliquots were oxidized with performic acid (20) and then hydrolyzed in 6 M HC1. Amino acid analyses ofpeptide hydrolysates were performed by using a Liquimat III amino acid analyzer (Kontron, Zurich, Switzerland) equipped with an ophthalaldehyde fluorescence detection system and a proline conversion accessory (21) . RESULTS
At a final dilution of 1:5000, the immune plasma S298 bound 30% of the "MI-labeled SS28-Tyr (SS28-' §5I-Tyr). In. the radioimmunoassay, the lowest detectable amount of SS28 was 35 pg. Specificity studies (Fig. 1) showed that S298 did not read SS14 but crossreacted minimally with SS28-(4-28) (< 1:2000). However, it read equimolar amounts of SS28-(1-12), [Met(0)8]SS28-(1-11), and SS28. Thus we can conclude that the antigenic determinant recognized by the immune plasma is contained in the SS28-(1-11) segment. Hypothalamic SS28- (1-12) . Sephadex G-50 chromatography of fresh rat hypothalamic extract revealed three zones of immunoreactivity ( Fig. 2A) . The first two zones were compatible with peptides having molecular weights corresponding to that of a somatostatin precursor of ca. 12,000 daltons (23) and with SS28. The third and major peak eluted in an area corresponding to a 1200-to 1300-dalton peptide. Initial purification ofthis third component was carried out with an acid extract of 3000 rat hypothalami by reverse-phase peptide extraction (yield: 52 mg of crude peptide fraction). Peptide isolation was then achieved after several steps on semipreparative HPLC (Fig. 3A) in the pyridine formate/1-propanol system (yield 14 ,g of SS28-Nt-LI) and analytical HPLC using the trifluoroacetic acid/acetonitrile mobile phase (Fig. 3B) . Two peaks of immunoreactive material containing 8.1 and 6.1 jg of SS28-Nt-LI were eluted. Finally, 1.8 Ag of pure peptide was isolated from peak II after two additional partitions in the same system, first using a shallower gradient (14-17% acetonitrile in 75 min, not shown), and then isocratic conditions (Fig. 4) . The peptide from peak I of Fig. 3B could not be purified to homogeneity due to losses encountered during final isolation steps. More starting material originating from 12,500 hypothalami was subjected to reversephase peptide extraction and semipreparative HPLC. At the second HPLC step (conditions as in Fig. 3B Table 1 . The composition of both peptides was identical in both cases to that of SS28- (1-12) . Furthermore, retention times in an isocratic reverse-phase HPLC system using 0.5% heptafluorobutyric acid/ 22% acetonitrile showed that synthetic SS28-(1-12)-OH co- ther purified on a C8 HPLC column using 0.5% trifluoroacetic acid with an acetonitrile gradient of 14-17% in 75 min (data not shown). The SS28-Nt-LI material eluted from that-column was refractionated on the same HPLC system, using 0.5% trifluoroacetic acid under isocratic conditions at 15% (vol/vol) acetonitrile. Flow rate, 0.6 ml/min; fraction size, 2.2 ml. Inj, injection. Pancreatic SS28- (1-12) . Sephadex G-50 chromatography of fresh rat. pancreatic extract revealed three zones of immunoreactivity (Fig. 2B) . The first two zones, accounting for 1.4% of the total SS28-Nt-LI eluted from the gel filtration column, were compatible with peptides of molecular weights corresponding to those ofprosomatostatin (ca. 12,000) and SS28. The third peak, accounting for 98.6% of the SS28-Nt-LI, corresponded to a peptide of molecular weight 1200-1400.
The starting material used for purification of this third component consisted of an acid extract from 439 rat pancreata that did not bind to an anti-SS14 immunoaffinity column. This unbound material was then submitted to reverse-phase peptide.
extraction, Sephadex G-50 fine. gel permeation chromatography, and two HPLC steps.
Two peaks of immunoreactive material were obtained, containing 9.7 ,ug (peak I) and 4.6 ,ug (peak II) of SS28-Nt-LI (Fig.  5) (Fig. 6) , and 4 jg of pure material was obtained from peak II with the same heptafluorobutyric acid/acetonitrile system. The two pancreatic peptides from peaks I and II had the same amino acid compositions as the two hypothalamic peptides (Table 1) . Both corresponded to the composition of SS28-(1-12). As had been observed for the peptides isolated from the hypothalamus, Proc. Nad. Acad. Sci. USA 79 (1982) above data we conclude that both rat pancreas and hypothalamus contain the dodecapeptide SS28- (1-12) . In both tissue extracts the [Met(0)8]SS28-(1-12) form was also observed, presumably due to oxidation during the isolation procedure.
Quantitation by RIA in fresh acid extracts after gel filtration indicates that SS28- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) and SS14 are present in approximately equimolar amounts (20-40 pmol per hypothalamus; 140-170 pmol per pancreas). On the other hand, in a rat anaplastic medullary thyroid carcinoma in which SS28 was present but no SS14 could be detected, we were unable to observe SS28-(1-12) (24) . These findings are consistent with the hypothesis that SS28 is the immediate biosynthetic precursor of both SS14 and SS28- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
An important issue remains as to whether SS28-(1-12) is endowed with any physiological role. On the basis of our own bioassays (effect on growth hormone, thyrotropin, and prolactin secretion in vitro), no biological function can be attributed to this dodecapeptide at the present time. Demonstrating that SS28-(1-12) is secreted would be interesting, although it could still represent a nonfunctional fragment cosecreted with SS14, a situation similar to the C-peptide for insulin (11) . On the other hand, because different natural peptide fragments from the same precursor may play different biological roles [as is the case, for example, with the pro-opiomelanocortin-derived fragments (25) ] SS28-(1-12) could possibly have a physiological role of its own. The results reported here add to the growing evidence of posttranslational processing of the precursor proteins ofbiologically active oligopeptides.
